Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Sirpiglenastat by Dracen Pharmaceuticals for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Sirpiglenastat is under clinical development by Dracen Pharmaceuticals and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...